...
首页> 外文期刊>Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies >Alteplase use for malfunctioning central venous catheters correlates with catheter-associated bloodstream infections
【24h】

Alteplase use for malfunctioning central venous catheters correlates with catheter-associated bloodstream infections

机译:阿替普酶用于中央静脉导管故障与导管相关的血流感染有关

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: A catheter thrombosis and the presence of a catheter-associated bloodstream infection (CBSI) often occur simultaneously, but it is unclear if or to what degree the two complications relate. Several animal and adult studies indicate a relationship between fibrin sheaths and thrombi in the development of CBSIs. To date, there has been limited human investigation in the pediatric population to determine a clear link between the presence of a thrombus and bacteremia. The use of alteplase for malfunctioning central venous catheter may indicate the formation of intraluminal thrombus or fibrin sheath. A catheter that requires alteplase is at higher risk of a CBSI. Design: A retrospective chart review from July 2008 to December 2010. Setting: PICU. Patients: All patients with central catheters admitted to the PICU. Interventions: No interventions performed with the retrospective study. MEASUREMENTS:: Number of total central venous catheters, number of central venous catheters that received treatment with alteplase, and number of CBSIs. MAIN RESULTS:: Preliminary data during the study period identified 3,289 central venous catheters. Twelve percent of these catheters required at least one dose of alteplase. There were 40 CBSIs during this same time period of which 28% received alteplase during the 5 days preceding the positive blood culture. The odds ratio for getting a CBSI when alteplase is administered is 2.87 (confidence interval 1.42-5.80; p = 0.002). The average age of the central venous catheters at time of infection was not statistically different, 16.1 days in the alteplase catheters compared with 25.6 days for the catheters that did not receive alteplase (p = 0.6). Conclusions: There is a positive correlation between the use of alteplase for malfunctioning central venous catheters and the development of a CASBI. This is likely associated with the presence of an intraluminal fibrin sheath or thrombus. This study adds evidence linking thrombus formation to CBSI. ? 2013 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
机译:目的:导管血栓形成和与导管相关的血流感染(CBSI)经常同时发生,但尚不清楚这两种并发症是否相关或在何种程度上相关。几项动物和成年研究表明,在CBSI的发展过程中,纤维蛋白鞘与血栓之间存在关联。迄今为止,在儿科人群中进行的人类研究非常有限,无法确定血栓与菌血症之间的明确联系。使用阿替普酶治疗中央静脉导管功能异常可能表明腔内血栓或纤维蛋白鞘形成。需要阿替普酶的导管患CBSI的风险更高。设计:2008年7月至2010年12月的回顾性图表审查。背景:PICU。患者:所有有中心导管的患者均被纳入PICU。干预措施:回顾性研究未进行干预。测量::中央静脉导管总数,接受阿替普酶治疗的中央静脉导管数量以及CBSI数量。主要结果:在研究期间的初步数据确定了3289中心静脉导管。这些导管的百分之十二需要至少一剂阿替普酶。在同一时间段内有40个CBSI,其中28%的CBSI在血液培养阳性之前的5天内接受了阿替普酶治疗。服用阿替普酶时获得CBSI的优势比为2.87(置信区间1.42-5.80; p = 0.002)。感染时中心静脉导管的平均年龄无统计学差异,在阿替普酶导管中为16.1天,而未接受阿替普酶的导管为25.6天(p = 0.6)。结论:阿替普酶治疗中央静脉导管出现故障与CASBI的发展之间存在正相关关系。这可能与管腔内纤维蛋白鞘或血栓的存在有关。这项研究增加了将血栓形成与CBSI相关联的证据。 ? 2013年由重症医学会和世界儿科重症和重症监护学会联合会颁发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号